James Healy

James Healy

Direktor/Vorstandsmitglied bei ARRIVENT BIOPHARMA, INC.

Vermögen: 110 Mio $ am 31.08.2026

61 Jahre
Health Technology
Finance
Commercial Services

Profil

Currently, James Irvin Healy is Director at Sorbent Therapeutics, Inc., Iterum Therapeutics International Ltd., Iterum Therapeutics US Holding Ltd., and Atsena Therapeutics, Inc. He serves as Independent Director at Arrivent BioPharma, Inc. (since 2023), Rapport Therapeutics, Inc. (since 2023), BioAge Labs, Inc. (since 2024), and Seaport Therapeutics, Inc. (since 2024).
He is General Partner at Sofinnova Venture Partners VII LP and Managing Partner at Sofinnova Investments, Inc. (since 2000), Sofinnova Management VI LLC, Sofinnova Management VII LLC (since 2012), and Sofinnova Investments, Inc. (Investment Management) (since 2000).
Formerly, he was Chairman at Hyperion Therapeutics, Inc. (2012–2015) and Y-mAbs Therapeutics, Inc. (2022–2025).
He was Vice Chairman at Auris Medical AG and Auris Medical Holding AG.
He served as Independent Non-Executive Director at Amarin Corp.
Plc (2012–2016), Independent Director at InterMune, Inc. (2011–2014), Anthera Pharmaceuticals, Inc. (2011–2014), Edge Therapeutics, Inc. (2015–2018), Ascendis Pharma A (2014–2022), NuCana Plc (2014–2022), Coherus Oncology, Inc. (2014–2022), Iterum Therapeutics Plc (2015–2020), and Natera, Inc. (2014–2025).
He was Director at CoTherix, Inc. (2001–2007), Novacea, Inc. (2001–2009), Movetis NV (2007–2010), PregLem SA (2009–2010), ObsEva SA (2013–2021), CinCor Pharma, Inc. (2019–2023), and others.
He was Lead Independent Director at Bolt Biotherapeutics, Inc. (2021–2024) and Independent Director at Karuna Therapeutics, Inc. (2019–2024).
Earlier roles include Manager at ISTA Pharmaceuticals, Inc. (1997–1998) and Associate at Sanderling Management CO LLC (1996).
Education includes undergraduate degree from the University of California, Berkeley (1990) and doctorate from Stanford University School of Medicine and Stanford University (1998).

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
10.06.2026 1.947.579 ( 4,06 % ) 95 Mio $ 31.08.2026
25.04.2025 46.260 ( 0,03 % ) 15 Mio $ 31.08.2026
10.06.2026 0 ( -.--% ) - $ 31.08.2026

Aktive Positionen von James Healy

UnternehmenPositionBeginn
ARRIVENT BIOPHARMA, INC. Direktor/Vorstandsmitglied 01.03.2023
RAPPORT THERAPEUTICS, INC. Direktor/Vorstandsmitglied 23.08.2023
BIOAGE LABS, INC. Direktor/Vorstandsmitglied 01.02.2024
Private Equity Investor 01.06.2000
Corporate Officer/Principal -
Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied -
Vorstandsvorsitzender 01.06.2000
Direktor/Vorstandsmitglied -
░░░░░░░░░ ░░░░░░░░░░ ░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ -

Ehemalige bekannte Positionen von James Healy

UnternehmenPositionEnde
░░░░ ░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░ ░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von James Healy im Detail an

Ausbildung von James Healy

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

66

Beziehungen ersten Grades

54

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen54

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Bayer Pharmaceuticals Corp.

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Finance

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Sofinnova Management VI LLC

Sofinnova Management VII LLC

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Finance

Health Technology

  1. Börse
  2. Insiders
  3. James Healy